source
- BioNTech-Genentech halts colorectal cancer vaccine trial after higher death rate in vaccine armBioNTech and Genentech stopped a phase 2 trial of their personalized mRNA vaccine BNT122 in patients with stage 2 or 3 colorectal cancer after an independent data safety monitoring board found more…
- Multispecific antibodies push CDMOs to redesign development platformsManufacturers are moving beyond traditional monoclonal-antibody platforms as multispecific therapeutics gain traction. The new design model relies on molecular engineering, advanced analytics, and…